Trials / Recruiting
RecruitingNCT06924970
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Agios Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tebapivat | Oral tablets. |
| DRUG | Tebapivat Matched Placebo | Oral tablets. |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
- First posted
- 2025-04-13
- Last updated
- 2026-03-30
Locations
32 sites across 7 countries: United States, Belgium, Canada, France, Ireland, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06924970. Inclusion in this directory is not an endorsement.